Detection of malignant tumours by multivariate analysis of proton magnetic resonance spectra of serum
- PMID: 2144752
- DOI: 10.1016/0277-5379(90)90091-7
Detection of malignant tumours by multivariate analysis of proton magnetic resonance spectra of serum
Abstract
Proton magnetic resonance spectra of blood serum have been subjected to multivariate data analysis to discriminate between samples from cancer patients and from controls. The main feature was the use of digitally defined resonance profiles. The methyl and methylene lipoprotein signals centred at 1.3 and 0.9 parts per million are non-lorentzian composite peaks that cannot be described properly by the line width at half-height. Instead 71 and 76 data points were used to describe the methylene and methyl peak profiles, respectively. These data points were used as input to a principal component analysis to distinguish between malignant (n = 29) and control samples (n = 55). At a probability level of 0.01 (F-test) modelling classified all patients except 2 correctly, while 1 control was slightly above the predictive level for malignancy.
Similar articles
-
Proton nuclear magnetic resonance spectroscopy of plasma lipoproteins in malignancy.Acta Oncol. 1988;27(5):479-82. doi: 10.3109/02841868809093574. Acta Oncol. 1988. PMID: 3203006
-
Assessment of proton nuclear magnetic resonance spectroscopy for detection of malignancy.Clin Chem. 1988 Mar;34(3):505-11. Clin Chem. 1988. PMID: 3349601
-
Detection of malignant tumors. Water-suppressed proton nuclear magnetic resonance spectroscopy of plasma.N Engl J Med. 1986 Nov 27;315(22):1369-76. doi: 10.1056/NEJM198611273152201. N Engl J Med. 1986. PMID: 3022146
-
Proton nuclear magnetic resonance spectroscopy of plasma lipoprotein: technical problems and potential interest in cancer disease.Anticancer Res. 1996 May-Jun;16(3B):1451-60. Anticancer Res. 1996. PMID: 8694513 Review.
-
The NMR blood test for cancer: current status.Cancer Cells. 1991 May;3(5):173-82. Cancer Cells. 1991. PMID: 1654067 Review.
Cited by
-
C-13 NMR spectroscopy of plasma reduces interference of hypertriglyceridemia in the H-1 NMR detection of malignancy. Application in patients with breast lesions.Breast Cancer Res Treat. 1991 May;18(2):99-110. doi: 10.1007/BF01980972. Breast Cancer Res Treat. 1991. PMID: 1912613 Clinical Trial.
-
MRS-based Metabolomics in Cancer Research.Magn Reson Insights. 2014 Feb 13;7:1-14. doi: 10.4137/MRI.S13755. eCollection 2014. Magn Reson Insights. 2014. PMID: 25114549 Free PMC article. Review.
-
Nuclear magnetic resonance spectroscopy of plasma to distinguish between malignant and benign diseases causing jaundice and cholestasis.J Cancer Res Clin Oncol. 1993;119(10):622-6. doi: 10.1007/BF01372726. J Cancer Res Clin Oncol. 1993. PMID: 8335681 Free PMC article.